Cardiff Oncology
David Einstein, MD, is an academic medical oncologist specializing in genitourinary cancers. After completing undergraduate work in the research-intensive Neurobiology track at Yale University, Dr. Einstein obtained his MD from Tufts University School of Medicine. Dr. Einstein completed his residency in internal medicine at Tufts Medical Center and a fellowship in hematology/oncology at Beth Israel Deaconess Medical Center.
Currently an attending physician at BIDMC and on faculty at Harvard Medical School, Dr. Einstein’s research includes translational studies supported by a grant from the Department of Defense. He also focuses on clinical trial development and serves as overall Principal Investigator for investigator-initiated trials at Dana-Farber/Harvard Cancer Center.
In addition to striving for better therapeutics, Dr. Einstein also aims to improve physician communication about difficult topics ranging from clinical trial enrollment to advance-care planning, and he has been an invited speaker at the Boston Prostate Cancer Support Group.
This person is not in the org chart
This person is not in any offices
Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.